Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round

26-Feb-2015 - Switzerland

Prexton Therapeutics announced the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital. MS Ventures, the company's founding investor, will also participate.
 
This first funding will help Prexton Therapeutics to develop novel small molecules that target the metabotropic Glutamate Receptor 4 (mGluR4) up to completion of Phase 1. This has the potential to improve motor complications in Parkinson’s disease patients. The compounds were originally licensed from Domain Therapeutics, a French biopharmaceutical R&D company specializing in G protein-coupled receptors (GPCRs).
 
In the course of this fundraising, Andreas Segerros of Sunstone and Raúl Martín-Ruiz of Ysios, will join the Board of Directors of Prexton. Jasper Bos will continue to represent MS Ventures.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances